Regenxbio RGNX EBITDA

EBITDA at other companies

Regeneron PharmaceuticalsREGN

$1.42B+16.7%

Sarepta Therapeutics, Inc.SRPT

$23.7M-81.3%

BioMarin PharmaceuticalsBMRN

$208.56M-29.4%

EyePoint, Inc.EYPT

-$96.69M-56.7%

Ultragenyx PharmaceuticalRARE

-$67M+32.3%

4D Molecular TherapeuticsFDMT

-$72.35M-37.6%

FAQ

What is Regenxbio's EBITDA?

Regenxbio (RGNX) reported EBITDA of $33.02M in Q2 2026.

How has Regenxbio's EBITDA changed year-over-year?

Regenxbio's EBITDA increased by 155.6% year-over-year, from -$59.37M to $33.02M.

What is the long-term trend for Regenxbio's EBITDA?

Over 4 years (2021 to 2025), Regenxbio's EBITDA has grown at a -3.7% compound annual growth rate (CAGR), from $169.54M to -$145.58M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.